Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia

Blood Coagul Fibrinolysis. 2021 Jul 1;32(5):349-351. doi: 10.1097/MBC.0000000000001026.

Abstract

Glanzmann thrombasthenia is an inherited disease causing bleeding episodes due to platelet dysfunction. The standard treatment for moderate-severe bleeding is platelet transfusion. Recombinant factor VIIa (rFVIIa) is successfully used in bleeding episodes and invasive procedures. Here, we present a patient with Glanzmann thrombasthenia, whose bleeding episodes could only be controlled by rFVIIa. The patient is a 28 years old male, who has had frequent bleeding episodes unresponsive to local hemostatic agents and tranexamic acid and had an anaphylactoid reaction to platelet transfusion. We started the patient on a low-dose (20 μg/kg) rFVIIa once a week. The patient has no spontaneous bleeding since then. This is the first case report of a Glanzmann thrombasthenia patient on routine prophylaxis with low-dose rFVIIa.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Factor VIIa / administration & dosage
  • Factor VIIa / therapeutic use*
  • Hemorrhage / etiology*
  • Hemorrhage / prevention & control*
  • Humans
  • Male
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Thrombasthenia / complications*

Substances

  • Recombinant Proteins
  • recombinant FVIIa
  • Factor VIIa